Attractive Targeted Sugar Bait Phase III Trial in Zambia

Malaria Clinical Trial

Official title: Attractive Targeted Sugar Bait Phase III Trial in Zambia

Status Active, not recruiting

Clinical Trial Summary

The trial will evaluate the efficacy of ATSB deployment plus universal coverage of a WHO core vector control (VC) interventions over two transmission seasons on a minimum 30% reduction in cohort clinical disease incidence, confirmed case incidence, and parasite prevalence, as compared with VC alone. Measurement of entomological outcomes, assessment of acceptability and barriers to uptake and consistent use of ATSB, safety and adverse event monitoring and estimation of the cost and cost-effectiveness of ATSB will also occur.

Clinical Trial Description

An open-label two-arm cluster randomized controlled trial (CRCT) design will be used comparing ATSB + LLINS vs LLINS alone (standard of care). A cluster trial design is indicated given the intended community-level effect of ATSBs on malaria transmission. Universal LLIN coverage will be ensured in both arms prior to start of the study and will serve as the standard of care. Arm 1 will receive ATSBs for two years. Arm 2 will receive the standard of care of universal LLIN coverage.

Sixty clusters will be used for the trial per site, with 30 clusters allocated to the ATSB intervention plus universal LLIN coverage arm, and 30 clusters allocated to the control with standard of care arm, universal LLIN coverage. Restricted randomization will be used to randomize the 60 clusters to intervention and control arms. The incidence cohort and cross-sectional household surveys will each be powered to detect a 30% reduction in the malaria outcome over two years.

Primary aim:

• Quantify the efficacy of ATSBs for reducing P. falciparum clinical case incidence, parasite prevalence, community infection incidence, and health facility confirmed malaria case incidence.

Secondary aims include:

• Quantify the efficacy of ATSBs for reducing target malaria vector density, altering the population age structure by reducing longevity, and reducing sporozoite and entomological inoculation rates (EIR).

• Assess the durability of the ATSB.

• Assess community acceptance of ATSB.

• Identify barriers to high and effective ATSB coverage.

• Understand the impact of ATSB deployment on LLIN use.

• Document cost and cost-effectiveness of ATSB deployment. ;

Related Conditions & MeSH terms

• Malaria
• Malaria, Falciparum
• Malaria,Falciparum
• Vector-Borne Transmission of Infection

• NCT number: NCT04800055
• Study type: Interventional
• Source: PATH
• Status: Active, not recruiting
• Phase: N/A
• Start date: December 1, 2020
• Completion date: December 31, 2023